TSX Venture: QPT
EDMONTON, May 1, 2020 /CNW/ - Quest PharmaTech Inc. (TSX-V:
QPT) ("Quest" or the "Company") announces the results from its
April 28, 2020 annual general meeting
of shareholders.
The Company is pleased to report that the following 4 directors
have been elected to the Company's Board of Directors:
Bin Huang, PhD.
Shawn Lu, CIM, MFin
W. John Meekison, CPA, CMA, P.Log,
CIM
Madi R. Madiyalakan, Ph.D.
"We are pleased with the AGM results and wish to thank our
shareholders for their continuing support," said Dr. Madi R.
Madiyalakan, Chief Executive Officer for Quest. "I would also
like to thank our outgoing Board members, Mr. Lorne Meikle, Ms. Norma
Beauchamp and Mr. Mark
Lievonen, for their service, and welcome our newly elected
Board member, Dr. Huang, who brings over 3 decades of senior
leadership experience in the corporate sector to her role,
including as Chief Executive Officer of SpeakEasy Cannabis Club
Ltd. and also having held executive positions at Emerald Health
Therapeutics and WEX Pharmaceuticals, can help to guide the Company
as it strives to add shareholder value. With the strength and
experience of our re-elected Board members, Mr. Meekison, Mr. Lu
and myself, I am confident that Quest's Board of Directors will be
able to help the Company execute its business strategy to add value
to our shareholders."
The re-appointment of the Company's auditors was also approved
at the meeting.
Approximately 48,700,000 shares were voted at the Company's
shareholder meeting, representing approximately 29% of the number
of common shares eligible to vote.
About Quest PharmaTech Inc.
Quest PharmaTech Inc is a
publicly traded, Canadian based biopharmaceutical company (QPT:
TSX-V) developing products to improve the quality of life. The
Company, through OncoQuest, and its Chinese joint venture,
OncoVent, is developing antibody-based immunotherapeutic products
for cancer. Quest has an ownership interest in Bioceltran which is
focused on SP Technology™ for transdermal delivery of drugs and
photosensitizers for pharmaceutical and cosmetic purposes. Quest
through its subsidiary, Madenco BioSciences, is developing
pharmaceutical products for dermatology and wound healing
applications. Quest, through its ownership interest in
OncoCare Therapeutics, is developing an antibody licensed from
University of Nebraska, AR 9.6 mAb
against truncated O-glycan on MUC16, for targeted cancer therapy
applications. To learn more, visit
www.questpharmatech.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Quest PharmaTech Inc.
